基诺美
可药性
药物重新定位
药物发现
重新调整用途
计算生物学
激酶
药品
医学
生物
卡波扎尼布
生物信息学
药理学
药物开发
癌症研究
细胞生物学
血管内皮生长因子受体
基因
生物化学
生态学
作者
Susan Klaeger,Stephanie Heinzlmeir,Mathias Wilhelm,Harald Polzer,Binje Vick,Paul-Albert Koenig,Maria Reinecke,Benjamin Ruprecht,Svenja Wiechmann,Chen Meng,Jana Zecha,Katrin Reiter,Huichao Qiao,Dominic Helm,Heiner Koch,Melanie Schoof,Giulia Canevari,Elena Casale,Stefania Re Depaolini,Annette Feuchtinger
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2017-11-30
卷期号:358 (6367)
被引量:829
标识
DOI:10.1126/science.aan4368
摘要
An atlas for drug interactions Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. There are hundreds of kinases within the human body, so knowing the kinase “target” of each drug is essential for developing successful treatment strategies. Sometimes clinical trials can fail because drugs bind more than one target. Yet sometimes off-target effects can be beneficial, and drugs can be repurposed for treatment of additional diseases. Klaeger et al. performed a comprehensive analysis of 243 kinase inhibitors that are either approved for use or in clinical trials. They provide an open-access resource of target summaries that could help researchers develop better drugs, understand how existing drugs work, and design more effective clinical trials. Science , this issue p. eaan4368
科研通智能强力驱动
Strongly Powered by AbleSci AI